Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors
- 28 December 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 14 (1), 61-68
- https://doi.org/10.1007/s10456-010-9195-8
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivoInternational Journal of Oncology, 2009
- Inhibition of endothelial progenitor cell differentiation by VEGIBlood, 2009
- Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growthProceedings of the National Academy of Sciences of the United States of America, 2008
- Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularizationJournal of Bone and Joint Surgery, 2007
- Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patientsAngiogenesis, 2006
- Functional disruption of α4 integrin mobilizes bone marrow–derived endothelial progenitors and augments ischemic neovascularizationThe Journal of Experimental Medicine, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Therapeutic stem and progenitor cell transplantation for organ vascularization and regenerationNature Medicine, 2003
- A novel secreted splice variant of vascular endothelial cell growth inhibitorThe FASEB Journal, 2002
- TL1, a Novel Tumor Necrosis Factor-like Cytokine, Induces Apoptosis in Endothelial Cells: INVOLVEMENT OF ACTIVATION OF STRESS PROTEIN KINASES (STRESS-ACTIVATED PROTEIN KINASE AND p38 MITOGEN-ACTIVATED PROTEIN KINASE) AND CASPASE-3-LIKE PROTEASEOnline Journal of Public Health Informatics, 1999